All Industries

FTN Network Releases 2024 NFL Draft Team Grades and Rookie Fantasy Scouting Guide Following 2024 NFL Draft

FTN Network

FTN Network, a company built for delivering affordable, customizable, and highly detailed NFL advanced charted data for betting, season-long fantasy, and daily fantasy, ushered the 2024 football season today with the release of its 2024 NFL Draft Team Grades and 2024 Rookie Fantasy Scouting Guide 2.0. The guide, which is authored by FTN President and Sirius XM Radio Host Jeff Ratcliffe, features rookie rankings, projections, veteran comps, dynasty value, trade value charts, draft boards, and more. FTN’s 2024 football season started on a high note with a successful weekend of NFL Draft coverage after providing NFL fans with some the most accurate set of mock drafts in the industry. In a field of 137 contestants, three FTN analysts finished in the top 15 of the FantasyPros mock draft accuracy contest: Tyler Loechner (4th place), Ratcliffe (13th), and Chris Meaney (14th). No other media company had two or more analysts finish inside the top 20 and Ratcliffe has now finished 13th or better in back-to-back years. FTN’s coverage included a live blog with instant reactions and fantasy projections from Ratcliffe for every fantasy-relevant rookie selected during the first three rounds of the draft. In addition to Ratcliffe’s projections and analysis, the coverage included insight from FTN’s Chief Analytics Officer and DVOA inventor Aaron Schatz, Mike Randle, Meaney, fantasy analyst Adam Pfeifer, and rookie expert Jeremy Popielarz. FTN also produced immediate, instant-reaction video breakdowns during the first night of the draft. “We provided fans with the most accurate information before the draft, live fantasy analysis during the draft across multiple mediums and the most comprehensive rookie fantasy scouting guide in the market,” said FTN Network CEO Perry Gershon. “Our extensive coverage of the NFL draft and our ongoing analysis of the incoming rookie class continues to prove that FTN is the one-stop-shop for NFL fans, fantasy players and bettors.” Along with pre, post and in-draft content, Randle gave all 32 NFL teams a 2024 Draft grade on the A-F scale. The Pittsburgh Steelers, Miami Dolphins and Los Angeles Chargers topped Randle’s charts with A+, A and A grades, respectively. The Carolina Panthers, Las Vegas Raiders and Dallas Cowboys rounded out the bottom of the 32 teams, receiving C grades. Additionally, Randle provided fantasy grades for every team that saw the Chargers score the highest (A+) and the Atlanta Falcons and Cowboys score the lowest (F). While Ratcliffe’s 2024 Rookie Fantasy Scouting Guide had been released prior to the draft, version 2.0 is now live and includes post-draft information. It can be found here. The guide includes 150 player-by-player breakdowns, draft boards, player comps, rankings for regular and superflex leagues, a dynasty rookie pick trade value chart and more and will be continuously updated before the start of the 2024 NFL season. About FTN Network FTN Network is a sports data B2B and fantasy sports and betting media B2C company. Founded in 2020, FTN gives the fantasy and sports betting community an edge through their own unique ecosystem - providing customizable tools that turn raw data into true insights while also offering expert analysis and content to help users make the best decision possible. Contact Details Hot Paper Lantern Sterling A. Randle +1 801-319-6153 srandle@hotpaperlantern.com

May 01, 2024 09:03 AM Eastern Daylight Time

Air|Water wraps up the largest Porsche gathering to hit Southern California

Luftgekuhlt

The second annual – and first standalone – Air|Water Porsche enthusiast show, produced by the Luftgekühlt events team, celebrated a tremendous success this weekend, with artistically curated cars attracting more than 11000 enthusiasts, who immersed themselves in the celebration of 75 years of everything Porsche. The team welcomed more than 1000 registered display cars spread throughout the 130 acre site at the Orange County Fair & Event Center. There was no shortage of discoverable experiences and aching feet. From the galleries created in the six main exhibition halls, to the off-road and rallye machines in the Action Sports Arena, the Broad Arrow Live Auction in The Hangar, and a sold-out exhibit hall featuring companies catering to the Porsche enthusiast, there was something for everybody at Air|Water. Also featured were 33 white Porsches in the Pacific Amphitheatre, custom restored builders in Park Plaza, and a barn full of vintage finds. The display cars even stretched across several expansive lots as Air|Water provided an unforgettable day for Porsche fans. In addition to spectacles such as a Porsche-powered Formula 1 car, Le Mans winners, and Pikes Peak entrants, visitors were able to meet VIPs including the show organizers and decorated racers Patrick Long and Jeff Zwart, plus Porsche Factory racers Jörg Bergmeister and Alwin Springer. While there were long lines at times for the clothing capsule and event merchandise, visitors and fans are now able to purchase any of the Air|Water items from the comfort of their sofa via luftgekuhlt.com/collections The entire Air|Water team would like to thank everybody who attended the show, the owners who displayed their cars, the brands that participated, the collectors who provided the extremely significant featured cars, and the event partners who contributed to the overall experience. It takes a village and we’re delighted to be part of yours! LUFTGEKÜHLT The next project for the team is the annual Luftgekühlt show. Dedicated purely to air-cooled Porsches and held at a unique location each year, the show has become a staple of the Porsche lifestyle calendar. Returning to Southern California in October this year, more details will be available via the Luftgekühlt social media channels and newsletter, which can be joined here: luftgekuhlt.com EDITOR’S NOTE Images from Air|Water 2024 are available here: dropbox.com/sh/zz14duvaes4t6br/AACT_4M-bs9v8lUbSqGSh6vja?dl=0 ABOUT AIR|WATER From the creators of Luftgekühlt comes the largest single-brand automotive experience to hit Southern California. Embarking on a fresh format that traces Porsche's journey from its inaugural moments to the contemporary masterpieces and most cutting-edge examples of today. For more information, visit air-water.com ABOUT LUFTGEKÜHLT In the Porsche vernacular, Luftgekühlt represents all the air-cooled cars in the manufacturer’s history, from the Pre-A 356 through the 993 model line, which ended in 1998. A true Porsche happening, Luftgekühlt is an experiential car culture event centered around a tightly curated list of historically significant or interesting cars, both street and race. There is no set formula for our events, but we're excited by cool venues, fun people, and creative expression, so you can bet those elements will always be included. The team strives to develop wild ideas that celebrate the passion we have for all things air-cooled, including exciting collaborations with likeminded people and brands. For more information, visit luftgekuhlt.com Contact Details Media Contact media@luftgekuhlt.com Company Website https://air-water.com/

May 01, 2024 05:55 AM Pacific Daylight Time

Image

News Release

Resouro Strategic Metals Inc. Files Prospectus for Proposed Dual-Listing on the ASX

Resouro Strategic Metals Inc.

Toronto, Ontario - ( The Newswire – May 1, 2024) – Resouro Strategic Metals Inc. ( TSX-V: RSM ) ( FSE: BU9 ) (OTC: RSGOGF) (" RSM ", " Resouro " or the " Company ") is pleased to announce that the Company has lodged a prospectus (" Prospectus ") with the Australian Securities and Investments Commission in relation to its proposed dual listing on the Australian Securities Exchange (“ ASX ”). Under the Prospectus the Company will offer 16,000,000 CHESS Depository Interests over common shares in the capital of the Company (“ CDIs ”) at an offer price of AUD$0.50 (approximately C$0.45) per CDI to raise gross proceeds of AUD$8.0 million (approximately C$7.2 million) ("the Offer "). Each CDI will represent a beneficial interest in 1 common share of Resouro. The Offer is expected to open on May 9, 2024 with the expected commencement of trading on the ASX to be on or around June 4, 2024. Taylor Collison Limited, an Australian broker, has been appointed as the Lead Manager for the ASX listing process. As compensation for its services, the Lead Manager will receive a capital raising fee of AUD$440,000 (approximately CAD$396,000), which is equal to 5.5% of the aggregate gross proceeds of the Offer and will be issued 1,843,643 stock options in the Company at an exercise price of AUD$0.75 (approximately CAD$0.68, vesting immediately, and expiring three years from the date of issue. Resouro plans to use the net proceeds raised pursuant to the dual listing to increase shareholder value through the identification, exploration, definition and development of its Tiros Project and Novo Mundo Project resources. The net proceeds will also be used to meet working capital requirements. Commenting on the additional listing, President, CEO and major shareholder of Resouro, Chris Eager, said: “We’re excited to take this important step towards broadening our investor base and enhancing liquidity. Australia’s vibrant capital market presents a compelling opportunity for Resouro to engage with a diverse group of investors who share our passion for rare earths, titanium and gold.” The dual listing is subject to regulatory approval and market conditions. Upon completion, Resouro’s shares will be tradable on the TSXV, the Frankfurt Stock Exchange (FSE), the Over-the-Counter market in the USA (OTC) and the ASX, providing investors with increased flexibility and accessibility. In accordance with section 734(6) of the Australian Corporations Act 2001 (Cth), the Company advises in respect of the offer of CDIs under the Prospectus: the issuer of the CDIs is Resouro Strategic Metals Inc. ARBN 671 716 457; the Prospectus is available online for Australian residents only at www.resouro.com or by contacting the Company by email at info@resouro.com; the offer of CDIs will only be made in, or accompanied by, a copy of the Prospectus; a person should consider the Prospectus in deciding whether to acquire the CDIs; anyone who wishes to acquire the CDIs will need to complete the application form that will be in, or will accompany, the Prospectus; the offer of CDIs under the Prospectus will only be made available to persons receiving the Prospectus in Australia and certain investors in Canada, New Zealand, Singapore, and the United Kingdom. A copy of the prospectus will be available on SEDAR+ at www.sedarplus.ca under the Company’s profile. However, CDIs may not be offered or sold within Canada or for the account of any Canadian residents except in transactions exempt from, or not subject to, the prospectus and registration requirements of applicable Canadian securities laws. About Resouro Strategic Metals Inc. Resouro is a Canadian-based mineral exploration and development company focused on the discovery and advancement of economic mineral projects in Brazil, including the rare earth elements and titanium Tiros Project and the Novo Mundo and Santa Angela gold projects. The Tiros Project, located in northern Minas Gerais, Brazil, is an early-stage exploration project focused on rare earth elements and titanium covering an area of approximately 450 km2. The Tiros Project comprises 17 exploration permits, and one exploration permit application held by the Company's Brazilian subsidiary; and 6 exploration permits and one exploration permit application that have been validly assigned to the Company's Brazilian subsidiary and are awaiting ANM approval. The Company holds, via its wholly owned Brazilian subsidiary, a 90% interest in the Tiros Project and the remaining 10% interest in the Tiros Project is held by RBM Consultoria Mineral Eireli (RBM), an unrelated third-party vendor. The Novo Mundo Project is located in the Alta Floresta Gold Province close to the northern border of the state of Mato Grosso, central Brazil. Within the licensed area is the small town of Novo Mundo, which is 30km west from the larger town of Guarantã do Norte. It comprises three exploration permits. The Company also has another interest in an exploration permit, being the Santa Angela Project, which is not considered material to the Company’s operations. Interests in the Novo Mundo Project and Santa Angela Project are held via the Company’s wholly owned subsidiary. For further information, please contact the Company at: Chris Eager, CEO chris.eager@resouro.com Phone: +44-738-805-7980 For Investor inquiries Info@Resouro.com On behalf of the Board of Directors, Chris Eager, President & CEO RESOURO STRATEGIC METALS INC. Learn more about the Company on its website: https://resouro.com Forward-Looking Information This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the completion of the Offer, the use of proceeds of the Offer and the proposed ASX listing. Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: general economic conditions in Canada and globally; industry conditions, including governmental regulation and environmental regulation; failure to obtain industry partner and other third party consents and approvals, if and when required, including obtaining final acceptance from the TSXV and the ASX; the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; stock market volatility; liabilities inherent in the mining industry; competition for, among other things, skilled personnel and supplies; incorrect assessments of the value of acquisitions; geological, technical, processing and transportation problems; changes in tax laws and incentive programs; failure to realize the anticipated benefits of acquisitions and dispositions; and the other factors. Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Due to the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of the content of this release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act ") or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

May 01, 2024 08:45 AM Eastern Daylight Time

Angkor Resources Celebrates Three Years Precedent ESG Agreement with Indigenous Communities on Gold Projects, Cambodia

Angkor Resources Corp.

GRANDE PRAIRIE, ALBERTA (May 1, 2024) - TheNewswire: ANGKOR RESOURCES CORP. (TSXV: ANK and OTCQB: ANKOF) (“ANGKOR ” or the “Company”) announces the third-year completion and celebration of Cambodia’s first national agreement with Indigenous Communities in Ratanakiri in the extractive sector. The agreement represents leading Environmental, Social, Governance (“ESG”) practices undertaken by Angkor across its projects. The agreement is the first of its kind in Cambodia – a national template between industry and Indigenous Communities that is long-term and covers all areas of development from prospecting through exploration, development, mining, and reclamation. The agreement between Angkor and Jarai communities in the Wild Boar Prospect area covers topics including clean water and sanitation solutions, health care, and economic development opportunities. Click Image To View Full Size Wild Boar Prospect with multiple surface samples with gold from 2.32 to 70.7 grams per tonne (“gpt”) of gold (“Au”) is one of the prospects in the agreement area. Local community members become part of the team in activities undertaken on their lands. At the request from the communities, Angkor also worked with Advanced Bank of Asia (ABA) to undertake projects to identify micro-finance exploitation that had become rampant and devastating to communities. Delayne Weeks, CEO comments, “We have some great gold and copper mineral projects in the area, and it has always been part of our philosophy to listen to their needs and work side by side with the local people who live on those lands. We believe it is a necessary component to long-term success in discovery and production of projects and we all win when we include the needs of everyone in the solutions and outcomes. We are immensely proud of this as a precedent in Cambodia; the past three years have progressed smoothly, without any conflict because we are all involved in the solutions.” Communities are members of the Jarai tribe, including six villages, many farms, and their communal lands cover an area of forty square kilometers across the Andong Meas exploration license of 118 square kilometers. In the past two months, additional Jarai communities in other areas have requested that Angkor consider similar agreements for and with their communities as well. Click Image To View Full Size Celebration activities included updates for all community members, a tribute to community land and local food production. Click Image To View Full Size Click Image To View Full Size The celebration took place in the shady areas of the surrounding forest to accommodate the sweltering +40C temperatures prevailing across Southeast Asia currently. QUALIFIED PERSON: Dennis Ouellette, B.Sc., P.Geo., is a member of The Association of Professional Engineers and Geoscientists of Alberta (APEGA #104257) and a Qualified Person as defined by National Instrument 43-101 (“NI 43-101”). He is the Company’s VP Exploration on site and has reviewed and approved the technical disclosure in this document. ABOUT ANGKOR RESOURCES CORPORATION: Angkor Resources Corp. is a public company, listed on the TSX-Venture Exchange, and is a leading resource optimizer working towards mineral and energy solutions across Canada and Cambodia. Angkor’s carbon capture and gas conservation project in Saskatchewan, Canada is part of its long-term commitment to Environmental and Social projects and cleaner energy solutions across expanding jurisdictions. The company holds three mineral exploration licenses in Cambodia, Andong Meas license and Oyadao North license in Ratanakiri Province and Andong Bor license straddling Oudar Meanchey and Banteay Meanchey Provinces. Angkor’s subsidiary, EnerCam Resources, was granted an onshore oil and gas license of 7300 square kilometers in the southwest quadrant of Cambodia. CONTACT: Delayne Weeks - CEO Email: info@angkorresources.com Website: angkorresources.com Telephone: +1 (780) 831-8722 Please follow @AngkorResources on LinkedIn, Facebook, Twitter, Instagram and YouTube. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.   The information in this press release contains certain forward-looking statements, including within the meaning of applicable securities laws. These statements relate to future events or our future intentions or performance. All statements other than statements of historical fact may be forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “continue”, “demonstrate”, “expect”, “may”, “can”, “will”, “believe”, “would” and similar expressions and include statements relating to, among other things, Angkor’s position, strategy and development plans and the benefits to be derived therefrom; the Corporation’s anticipated annual production growth and annual capital spending for the next three years; that the focus of the Corporation’s development activities during the remainder of 2023; expectations of when the transaction is completed; the anticipated focus of Angkor’s operations in 2024; the Corporation’s anticipated 2024 average production; and the Corporation’s expectations that it will continue to deliver clean, reliable, sustainable energy, contributing to a reduction in global emissions by displacing high-carbon fuels. Angkor’s actual decisions, activities, results, performance or achievement could differ materially from those expressed in, or implied by, such forward-looking statements and accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur or, if any of them do, what benefits that Angkor will derive from them.

May 01, 2024 08:40 AM Eastern Daylight Time

Image

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Artificial intelligence (AI) is on the cusp of transforming nearly every single industry. When it comes to healthcare, several trends have emerged. As doctors and scientists continue to innovate, the market for AI in healthcare is expanding. The AI healthcare market appears poised for growth, with a market size of $22 billion in 2023 – a number that’s expected to accelerate at a CAGR of 36.4% from 2024-2030. The market for AI in healthcare is expected to reach $187.95 billion by 2030, demonstrating the transformative shift it’s brought to the healthcare industry. AI-focused healthcare companies are driving this progress. Here is how three healthcare companies are harnessing AI’s capabilities, using technology to drive innovation, target treatments and increase access to healthcare. Driving Innovation The rapidly growing field of AI in healthcare is already coming to life at places like the Mayo Clinic, where several AI-powered medical and surgical improvements have validated new approaches to clinical care in cardiovascular medicine, neurology, oncology, radiology and other fields of medicine. AI is replacing repetitive, manual processes – such as patient data analysis – that slow down healthcare professionals. Moving forward, this new technology will drive innovation, executives at Moderna (NASDAQ: MRNA) said after inking a partnership with OpenAI, the company behind ChatGPT, in April. The move gave about 3,000 Moderna employees access to ChatGPT Enterprise, built on OpenAI’s most advanced language model, GPT-4, the Wall Street Journal reports. Moderna anticipates the integration of AI could lead to the introduction of 15 new products by 2029, the Cambridge, Mass., company said. Moderna CEO Stéphane Bancel envisions employees using ChatGPT at least 20 times a day to “reinvent all of Moderna's business processes,” leading to greater overall efficiency. Here’s one example. When developing medicines, researchers study the biological and genetic variations that cause diseases to develop. Utilizing AI to dissect medical data sets like lab results can help scientists fill in the missing pieces. AI can assist them in figuring out the root cause of the disease, helping get much-needed treatments to patients faster. AI can lift success rates to up to 50% while reducing a drug’s time-to-market, a recent Moderna study by Harvard University’s Digital Data Design Institute found. AI is already transforming Moderna and enhancing its value-creation process. The company’s position in AI-powered innovation is leading to more efficiency and scalability across the value chain due in large part to an AI-centric culture. As of October 2023, nearly 65% of Moderna employees were active AI users. They have used the tool in multiple specific functions, from customized support to meaningful improvements in workflow efficiency and efficacy. Moderna has plans to integrate AI into all aspects of the drug development life cycle. To that end, the company has launched the Moderna AI Academy to accelerate training on AI throughout the organization. Targeted Treatments In addition to advancing drug discovery, artificial intelligence is also helping treatments reach patients faster. The past decade has seen an explosion in the amount of health data available to doctors. Organizing and analyzing this much data in a timely manner, however, can be a complex and time-consuming task for the human mind, no matter how capable or intelligent the person. That’s where AI comes in. AI is enabling researchers to develop more targeted medicines, driving progress in the field of precision medicine. This trend was part of a presentation delivered by executives at Johnson & Johnson (NYSE: JNJ), who hosted a panel discussion about AI’s role in transforming healthcare at this year’s South by Southwest conference. They touched on many topics, from AI applications in drug discovery to its ability to assist doctors during clinical trials. When it comes to running clinical trials, one of the biggest challenges is quickly and efficiently recruiting and enrolling patients who meet the selection criteria. By applying AI technology to the early stages of a clinical trial, Johnson & Johnson researchers can use large anonymized datasets to identify and locate clinical research sites with patients who could potentially benefit from the Johnson & Johnson medicines that are being studied. From there, the clinical trial operations team can work to determine the likelihood of enrolling the newly identified sites into their trials. “Historically, many clinical trials have largely taken place at major academic medical centers, but we know that not all patients have access to these centers,” said Nicole Turner, Senior Director of Global Development, Data Science & Digital Health and R&D at Janssen Pharmaceuticals. “Our goal is to leverage the power of AI to bring trials to more patients, rather than waiting for patients to come to us.” According to The Wall Street Journal, Johnson & Johnson continues to make investments – to the tune of hundreds of millions of dollars – in AI and data science. The company has hired about 6,000 data science and digital experts and opened a new research facility near San Francisco, and company executives say AI will power the company’s drug discovery work and strengthen its pharmaceuticals business in the future. Increasing Access Across the country, there is a need for more accessible and systemic healthcare solutions. One company is responding by using AI to combat cardiovascular diseases globally while committing to health equity and access. AI algorithms can effectively handle and analyze extensive medical data, including DNA biomarkers such as epigenetic and genetic information. As such, the shift to digital health and AI-driven diagnostics could also have widespread impacts on the cardiovascular detection, care and management industry, helping increase access to healthcare in a timely manner across the board – especially helping underserved communities in the process. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and detection more precise, was formed to improve patient outcomes by developing and commercializing clinical tests that leverage AI-driven technology to combat cardiovascular disease. The company is behind PrecisionCHD TM, the first integrated genetic-epigenetic test for the detection of coronary heart disease (CHD), the most common type of heart disease and the cause of most heart attacks. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses AI, along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD and use the information for more personalized patient management. Cardio Diagnostics has also developed Epi+Gen CHD TM, a powerful test that predicts the three-year risk for a CHD event, mainly a heart attack. Powered by AI-driven integrated genetics-epigenetics, the tool enables more effective decision-making and earlier interventions. Traditional diagnostic methods for CHD, often inaccessible due to the need for specialized infrastructure, can be invasive and sometimes require exposure to ionizing radiation. Additionally, some of the tests are not sensitive to all forms of CHD and can be very costly, resulting in millions of Americans left without adequate and potentially lifesaving cardiac care. Thanks to AI, PrecisionCHD has armed clinicians with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test. For rural communities where access to specialized medical facilities is limited, the implications of this advancement are particularly relevant. With only a simple blood draw needed to complete a test, PrecisionCHD offers patients in underserved areas access to state-of-the-art cardiac assessments. PrecisionCHD can be administered in primary care or telemedicine settings, significantly reducing the need for patients to travel to distant specialized clinics. This level of availability, marking a step forward toward mitigating healthcare disparities, would not be possible without AI. Featured photo by CDC on Unsplash. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

May 01, 2024 08:30 AM Eastern Daylight Time

Image

News Release

Generation Uranium Commences Trading on the Frankfurt Stock Exchange

Generation Uranium Inc

Vancouver, British Columbia, Canada, May 1st, 2024 – Generation Uranium Inc. (the “Company” or “Generation”), (TSXV: GEN) is pleased to announce the listing of its common shares on the Frankfurt Stock Exchange (“FSE”) under the symbol “W85”. The Company officially began trading on the FSE on April 26 th and the event marks a significant milestone in the Company’s expansion into European investment markets. With its status as a prominent European listing venue, the Frankfurt Stock Exchange plays an important role in facilitating trading activities, handling around 90 percent of all securities traded within Germany. Companies listing on the FSE often aim to enhance shareholder accessibility and foster investment opportunities for a global audience of investors. “We are excited about Generation’s entry into the European capital markets through our Frankfurt Stock Exchange listing. As Germany’s premier stock exchange, it marks a significant milestone in our efforts to expand our reach with investors overseas,” stated Generation President and Chief Executive Officer, Anthony Zelen. “Listing on the FSE should serve to increase liquidity and our visibility on a global scale.” For more information on our impending uranium exploration activities in the Thelon Basin, please visit our investor presentation and website. FOR FURTHER INFORMATION CONTACT Anthony Zelen President and Chief Executive Officer admin@generationuranium.com 778-388-5258 About Generation Uranium The Company is a natural resource company engaged in the exploration and development of mineral properties. The Company holds an option to acquire a 60% interest in and to the Arlington Property, located within the Arrow Boundary District of south-central British Columbia, and holds a 100% interest in the Yath Uranium Project, located in the Territory of Nunavut. Forward-Looking Statements This news release contains certain forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to, market conditions, availability of financing, actual results of the Company’s exploration and other activities, environmental risks, future metal prices, operating risks, accidents, labor issues, delays in obtaining governmental approvals and permits, and other risks in the mining industry. All the forward-looking statements made in this news release are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

May 01, 2024 08:00 AM Eastern Daylight Time

News Release

Middle East’s $9 Billion EV Opportunity Reaffirms Potential In These Stocks

VVPR, VFS, NWTN, LCID

The Middle East, a region long known for its oil and gas riches, is transitioning to a new, more sustainable future, potentially dominated by electric vehicles. The UAE, for instance, has launched several initiatives over the past years to encourage the adoption of EVs among its residents. Strategies like the Dubai Green Mobility Strategy 2030 aim to have around 42,000 electric cars on Dubai’s streets by the end of this decade. Currently, the UAE is ranked 7th globally and is the top country in the MENA region on the Global Electric Mobility Readiness Index (Gemrix), demonstrating the nation’s dedication to sustainable transportation and its goal of achieving carbon neutrality by 2050. Like the UAE, the Saudi government has also taken significant steps to drive EV adoption, including funding infrastructure. Since 2021, the Saudi Electric Vehicle Charging Infrastructure Development Initiative (SEVCIDI) has been working towards a goal of installing 50,000 domestic charging stations by 2025. According to analysts, EV adoption will gain major momentum in the Middle East thanks to growing tech-savvy urban hubs in Saudi Arabia and the UAE, in addition to a significant drop in the cost of EVs over the past years. With EV sales looking set to continue ramping up, here are four stocks that seem well positioned to capitalize on the region’s growth. VivoPower International PLC (NASDAQ:VVPR), a sustainable energy solutions (SES) company, is on a mission to make the cost of owning an EV much more affordable without compromising on any of the features. The company’s flagship subsidiary, Tembo e-LV, supplies conversion kits containing all the parts needed to convert a vehicle from an internal combustion engine to electric. These parts include the batteries, an e-motor, a reduction box, a charger, software, and many other components that make the converted vehicle work safely and seamlessly. In essence, the Tembo electric utility vehicle (EUV) conversion kits will transform new and second-hand diesel-powered 4x4 LandCruiser and Hilux vehicles into ruggedized EUVs that can operate in the harshest of terrains, like in mining and other industrial applications. Tembo’s conversion kits have seen significant interest from not only the Middle East but also the African market, as illustrated by its recent securing of a commitment of 5000+ kits and an order pipeline of 10,000+ kits. Those included an MOU in Jordan for 1,000 kits, opening a path to the Middle East, which is the largest Landcruiser market, and a definitive agreement in Kenya for 4,000 kits, providing entry into second-hand vehicle segments, which expands the company’s addressable market. To put the opportunity in context, the Middle East and Africa EV markets were worth about $3.33 billion in 2024 and are expected to reach $9.42 billion by 2029, representing a CAGR of 23.20%, according to research from Mordor Intelligence. VVPR is well positioned to capitalize on this growth and has what could possibly be one of the best backers to help advance in the region. That is because earlier this month, Vivo received a direct investment of $10 million into Tembo at a pre-money valuation of $120 million, from a private investment office of a member of the ruling Al Maktoum family of Dubai. At the moment, VVPR has a market cap of about $12.5 million, which implies that its valuation has significant upside potential even without taking into account its other subsidiaries, which it is divesting from. Just this week, VivoPower International PLC (NASDAQ:VVPR) announced that it entered into a definitive asset sale agreement for the sale of one of its non-core business units, Kenshaw Electrical, to ARA Group Limited, a leading diversified industrial services group based in Australia, for a total of A$5 million. This follows another announcement that it would spin off the majority of its Caret business unit’s portfolio, representing up to ten solar projects totaling 586 MW-DC at varying stages of development. This is in line with VivoPower’s previously announced strategy to focus on reinvesting in its strong growth businesses, including Tembo. It is also important to note that Tembo will be going public via a merger with Nasdaq-listed SPAC Cactus Acquisition Corp. (CCTS). CCTS will issue 83.8 million shares in exchange for Tembo shares at $10 per CCTS share, which corresponds to a pre-money indicative equity valuation of Tembo of $838 million. VivoPower shareholders will get 5 Tembo shares worth $10 each for every share held, in addition to a special dividend at $1 per share, translating to another $5 per VivoPower share held. This deal has the potential to unlock significant shareholder value since even if the Tembo share price upon IPO is only $1, this implies a per share valuation for VVPR of $28, including the value of dividend shares. VinFast Auto Ltd. (NASDAQ:VFS) marked a significant milestone in its global expansion strategy by entering into a dealer sales agreement with Bahwan Automobiles Trading LLC (BAT) for the distribution of electric vehicles (EVs) in Oman. This collaboration not only introduces VinFast's presence in the Middle East but also underscores the company's commitment to promoting green mobility solutions worldwide. The deal follows an Initial Memorandum of Understanding for Cooperation signed at the COP 28 conference in the United Arab Emirates (UAE) in 2023. It makes BAT the official dealer of VinFast in Oman. Under the agreement, BAT is to establish 13 VinFast stores and service locations over the next three years. The first store is expected to launch in mid-2024, with vehicle sales commencing shortly after. VinFast will also collaborate with BAT to introduce four e-SUV models in the Omani market: VF 6, VF 7, VF 8, and VF 9. Mr. Ta Xuan Hien, CEO of VinFast Middle East, said: "Oman presents a promising market for electric vehicles, as consumers in the nation demonstrate a growing interest in sustainable and environmentally friendly transportation solutions. We are confident that this dealer sales agreement with BAT, a leading and highly reputable dealer in Oman, will empower VinFast to swiftly establish a presence in the market and provide customers in the country with the most diverse and high-quality selection of electric vehicles available." NWTN (NASDAQ:NWTN) is a Dubai-based pioneering green energy company dedicated to providing passenger-focused, premium electric vehicle products and green energy solutions to customers worldwide. The company has a full vehicle assembly facility in Abu Dhabi. In January this year, NWTN’s strategic partner, W Motors, a leading manufacturer of high-performance luxury cars in the Middle East, signed a partnership agreement with Manaseer Group. Through this agreement, Manaseer Group will be the exclusive distributor for W Motors and NWTN vehicles in Jordan and the Middle East and Africa region. It will use its facilities as a factory for assembly and thereafter manufacturing operations for these new car brands, which is made possible by Manaseer’s strong presence and expertise of the Jordan market, and its commitment to providing environment-friendly solutions that combine innovation and luxury. The agreement was reached following Manaseer Group's recent participation in the Higher and Executive Committees for Integrated Industrial Partnership meeting that took place in Bahrain. Manaseer Group’s Vice Chairman Eng Abdel Rhman Obaid said: "We are proud to have represented Jordan in the Higher and Executive Committees for Integrated Industrial Partnership meeting and to contribute to the industry's development in Jordan and the region, as we believe in our role in the industrial sector empowerment.” Lucid Group, Inc. (NASDAQ:LCID) officially opened the first-ever car manufacturing facility in Saudi Arabia last year, making it its second Advanced Manufacturing Plant (AMP-2) and first international plant. The facility will produce Lucid's groundbreaking electric vehicles for Saudi Arabia and export them to other markets. The AMP-2 facility received significant support from the Ministry of Investment of Saudi Arabia (MISA), the Saudi Industrial Development Fund (SIDF), and the Economic City at King Abdullah Economic City (KAEC) and is expected to play a pivotal role in accelerating Saudi Arabia's strategic goal to diversify its economy. The AMP-2 facility has begun semi knocked-down (SKD) assembly and is expected to have an annual capacity of 5,000 cars. The initial operation re-assembles Lucid Air vehicle 'kits' that are pre-manufactured at the company's U.S. AMP-1 Manufacturing Facility in Casa Grande, Arizona. Lucid aims to transition AMP-2 to complete build unit (CBU) production after the middle of the decade, with an additional annual capacity of 150,000 cars. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, or assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. Capital Gains Report (CGR) owned by RazorPitch Inc. is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR has been retained by VivoPower International PLC. to produce and distribute this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website capitalgainsreport.com All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content. Contact Details Mark McKelvie +1 585-301-7700 markrmckelvie@gmail.com Company Website http://razorpitch.com

May 01, 2024 08:00 AM Eastern Daylight Time

CONSENSUS HEALTH WINS TWO STEVIE® AWARDS IN 2024 AMERICAN BUSINESS AWARDS®

Consensus Health

Consensus Health, a leading New Jersey-based healthcare organization with a physician-led medical group and an Independent Physician Alliance (IPA), announced today it was named winner of two Stevie® Awards in The 22nd Annual American Business Awards®. Consensus Health earned both a silver Stevie Award in the Company of the Year - Health Products & Services – Large category as well as a bronze for Achievement in Growth. Consensus Health was recognized for its growth, distinctive model and commitment to the delivery of quality healthcare across New Jersey. The care it brings to the New Jersey community, based on the clinical autonomy afforded its physicians, has elevated the Company’s presence throughout New Jersey, as evidenced by its network of 166 physicians across 56 practices that span 69 locations statewide. The American Business Awards are the U.S.A.’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Nicknamed the Stevie’s for the Greek word meaning “crowned,” the awards will be presented to winners at a gala ceremony at the Marriott Marquis Hotel in New York on Tuesday, June 11. Tickets are now on sale. More than 3,700 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories. “On behalf of the entire Consensus Health team, we thank the judges of the American Business Awards for recognizing the role our Company plays amid an ever-changing healthcare landscape. The niche model we’ve carved out in New Jersey emphasizes the independent physician and applauds clinical autonomy, which has allowed Consensus Health to achieve successes in the areas of improved patient outcomes and proven value-based care actions and outcomes. A sincere thank you goes out to our team statewide; they are on the front lines – day in and day out – truly impacting the quality care and service we bring patients. It is this dedication that reaped the successes which were honored in this prestigious awards program,” explained Michael Lovett, Consensus Health chief executive officer. “When I became the first Consensus Health Medical Group physician in 2018, I never imagined where we’d be today. Now, with nearly 200 physicians throughout New Jersey, we are truly impacting patient health through our ever-growing network of independent physicians spanning primary care and as well as many areas of specialty. Our unrelenting commitment to quality care is attributed to this prominent placement within the ABAs. Thank you to all who made these accolades possible,” said Marc Feingold, MD, Consensus Health medical director. Details about The American Business Awards and the list of 2024 Stevie winners are available at www.StevieAwards.com/ABA. About the Stevie Awards Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, and the new Stevie Awards for Technology Excellence. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevie’s recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com. About Consensus Health Marlton, New Jersey-based Consensus Health is a leading physician-owned and -governed medical group comprised of New Jersey-based independent primary care providers and specialty doctors. Consensus Health affords its 166 member physicians across 56 practices and 69 locations clinical autonomy, which enables them to focus on the delivery of high levels of patient care within the local markets they each serve. Currently, Consensus Health provides medical care statewide throughout 18 New Jersey counties. For more information, visit www.consensushealth.com or connect with the Company on LinkedIn. Contact Details PAIRELATIONS, LLC Susan J. Turkell +1 303-766-4343 sturkell@pairelations.com

May 01, 2024 08:00 AM Eastern Daylight Time

News Release

Sernova Announces AGM Voting Results

Sernova Corp.

LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, is pleased to announce results from its Annual General Meeting of Shareholders (the “AGM”) held virtually via live audio webcast, on April 30, 2024. At the Meeting, a total of 88,316,160 common shares were voted, representing 29.11% of the votes attached to all outstanding common shares as of the record date. The voting results were as follows: Accordingly, Cynthia Pussinen, James T. Parsons, Dr. Steven Sangha and Brett A. Whalen were elected to the board of directors for the ensuing year. In addition, Bernd Muehlenweg was appointed to the board of directors following the AGM. Bertram Plettenberg resigned from the board of directors prior to the AGM and did not stand for election at the AGM. Shareholders also approved (with 99.79% of the votes approving) the re-appointment of KPMG LLP, Chartered Professional Accountants as the Company’s auditor for the ensuing year, and approved (with 82.57% of the votes approving) the amendments to the Option Plan and DSU Plan and the increase in the maximum number of Common Shares reserved for issuance. ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago. Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A. FOR FURTHER INFORMATION, PLEASE CONTACT: Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com 519-902-7923 www.sernova.com FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

May 01, 2024 07:00 AM Eastern Daylight Time

1 ... 3 4 5 6 7 ... 3470

Back